Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
The stock has hit Higher high. Tech stocks are falling apart and boom to PFE
Chart looks good. Next resistance is 26.92. Once it breaks the resistance, next hit point will be 27.01.
Can Merck's KEYTRUDA Transform Head and Neck Cancer Treatment After 20-Year Stagnation?
Can This Summit-Pfizer Cancer Drug Combo Revolutionize Solid Tumor Treatment?
As I've been suggesting recently, this sell-off was likely to occur for a couple of key reasons. We’ve had a round of bad news, so we are awaiting good news to break us higher. But traders are bracing for dis...
A nice double bottom pattern in the chart. The stock is trading above 5 EMA, 10 EMA, 20 EMA, 60 EMA and 120 EMA. The trend is up. Once it breaks above $27, the trend is confirmed bullish.
Chart looks good. Next resistance is 26.47. Once it breaks the resistance, next hit point will be 26.69.
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Summit on Monday said the companies plan to evaluate ivonescimab in combination with several Pfizer ADCs across multiple solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations.
Miami biopharmaceutical company Summit said it will provide ivonescimab for...
No comment yet